

Lambert-Hall, Alecia

From: French, Cecelia
Sent: Thursday, December 01, 2011 3:31 PM
To: Lambert-Hall, Alecia
Subject: FW: NDSAC Final Recommendations for NSAIDs available on the Canadian market (excluding ASA and acetaminophen)

Cecelia French, MSt, BSW, AHIP
 Director, Information Services

OptumInsight
 4 Innovation Drive
 Dundas, Ontario L9H 7P3
 Canada

T +1 905 690-5526
 F +1 905 689-1465

cfrench@canreginc.com
www.canreginc.com

CanReg is now OptumInsight part of Optum™
From many distinct and powerful brands emerges one company that spans the evidence lifecycle.

CanReg, the leading global regulatory strategy consultancy, has joined forces with fellow industry leaders **ChinaGate**, a leading Shanghai-based advisory firm with Chinese-market regulatory expertise, **Quality Metric**, creators of the industry-standard SF health surveys, **HTAnalysts**, specialists in evidence-based medicine and reimbursement for health care technologies, and **Innovus**, the market access, economic modeling and late phase research leader, to offer you expanded life sciences capabilities as **OptumInsight**. This new organization will help our clients leverage the depth of our services throughout the health ecosystem by providing analytics, technology and consulting services that better enable decisions and results.

From: Lynn Rush [mailto:lrush@NAPRA.CA]
Sent: Wednesday, November 16, 2011 3:47 PM
To: info
Subject: NDSAC Final Recommendations for NSAIDs available on the Canadian market (excluding ASA and acetaminophen)

The Initial Recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) on September 11-12, 2011 for the scheduling of:

- Ibuprofen and its salts containing 400 mg or less per oral dosage unit (when sold in package sizes of up to 18,000 mg) **Unscheduled (no change)**
- Ibuprofen and its salts containing 400 mg or less per oral dosage unit (when sold in package sizes exceeding 18,000 mg) **Schedule III (from Unscheduled)**
- Naproxen sodium 220 mg per oral dosage unit (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes of up to 6,600 mg) **Unscheduled (no change)**
- Naproxen sodium 220mg per oral dosage unit (when sold in products labelled with a recommended maximum daily dose of 440 mg, and in package sizes exceeding 6,600 mg) **Schedule III (no change)**
- Diclofenac diethylamine in preparations for topical use on the skin in concentrations of not more than the

equivalent of 1% diclofenac **Unscheduled (no change)**

were finalized effective November 16, 2011. Final approval of the Initial Recommendations were made by NAPRA's Executive Committee, in consideration of comments received during the 30-day review period. The National Drug Schedules will be amended accordingly.